Net Cash Provided by (Used in) Financing Activities of Citius Pharmaceuticals, Inc. from 31 Dec 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Citius Pharmaceuticals, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2010 to 31 Dec 2025.
  • Citius Pharmaceuticals, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Dec 2025 was $20,877,925, a 711% increase year-over-year.
  • Citius Pharmaceuticals, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $33,303,148, a 234% increase from 2024.
  • Citius Pharmaceuticals, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $9,972,327, a 28% decline from 2023.
  • Citius Pharmaceuticals, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $13,829,450.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Citius Pharmaceuticals, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $20,877,925 +$18,303,874 +711% 01 Oct 2025 31 Dec 2025 10-Q 13 Feb 2026 2026 Q1
Q4 2024 $2,574,051 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2026 2026 Q1
Q4 2020 $500* +$394 01 Oct 2020 31 Dec 2020 10-Q 10 Feb 2022 2022 Q1
Q4 2019 $106* -$15,894 01 Oct 2019 31 Dec 2019 10-Q 11 Feb 2021 2021 Q1
Q4 2018 $16,000 -$6,591,671 -100% 01 Oct 2018 31 Dec 2018 10-Q 13 Feb 2020 2020 Q1
Q4 2017 $6,607,671 +$5,540,466 +519% 01 Oct 2017 31 Dec 2017 10-Q 14 Feb 2019 2019 Q1
Q4 2016 $1,067,205 +$764,767 +253% 01 Oct 2016 31 Dec 2016 10-Q 14 Feb 2018 2018 Q1
Q4 2015 $302,438 01 Oct 2015 31 Dec 2015 10-Q 14 Feb 2017 2017 Q1
Q4 2013 $575,000 +$574,800 01 Oct 2013 31 Dec 2013 10-Q 17 Feb 2015 2015 Q1
Q4 2012 $200* -$2,000 01 Oct 2012 31 Dec 2012 10-Q 19 Feb 2014 2014 Q1
Q4 2011 $2,200* -$1,497,800 01 Oct 2011 31 Dec 2011 10-Q 08 Feb 2013 2013 Q1
Q4 2010 $1,500,000 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012 2012 Q1

Citius Pharmaceuticals, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $33,303,148 +$23,330,821 +234% 01 Oct 2024 30 Sep 2025 10-K 23 Dec 2025 2025 FY
2024 $9,972,327 -$3,857,123 -28% 01 Oct 2023 30 Sep 2024 10-K 23 Dec 2025 2025 FY
2023 $13,829,450 01 Oct 2022 30 Sep 2023 10-K 27 Dec 2024 2024 FY
2021 $120,470,550 +$97,572,117 +426% 01 Oct 2020 30 Sep 2021 10-K 22 Dec 2022 2022 FY
2020 $22,898,433 +$11,750,881 +105% 01 Oct 2019 30 Sep 2020 10-K 15 Dec 2021 2021 FY
2019 $11,147,552 -$6,150,481 -36% 01 Oct 2018 30 Sep 2019 10-K 16 Dec 2020 2020 FY
2018 $17,298,033 +$6,414,945 +59% 01 Oct 2017 30 Sep 2018 10-K 16 Dec 2019 2019 FY
2017 $10,883,088 +$5,620,201 +107% 01 Oct 2016 30 Sep 2017 10-K 16 Dec 2019 2019 FY
2016 $5,262,887 +$3,753,394 +249% 01 Oct 2015 30 Sep 2016 10-K 11 Dec 2018 2018 FY
2015 $1,509,493 -$171,341 -10% 01 Oct 2014 30 Sep 2015 10-K 13 Dec 2017 2017 FY
2014 $1,680,834 +$572,834 +52% 01 Oct 2013 30 Sep 2014 10-K 23 Dec 2016 2016 FY
2013 $1,108,000 +$208,000 +23% 01 Jan 2013 31 Dec 2013 10-K 14 Dec 2015 2015 FY
2012 $900,000 +$881,507 +4767% 01 Jan 2012 31 Dec 2012 10-KT 29 Dec 2014 2014 FY
2011 $18,493 01 Oct 2010 30 Sep 2011 10-K 15 Jan 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.